Search Results

You are looking at 201 - 210 of 483 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules

Betsy L. Althaus

increasing dose intensity . Am J Clin Oncol 1999 ; 22 : 38 – 41 . 22. Livingston RB Ellis GK Gralow JR . Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

Full access

Clinical Trials: Does One Size Really Fit All?

Margaret Tempero

metastatic to liver. He asked if we had a clinical trial he could participate in. I explained that we did, but that the chemotherapy backbone of the trial was gemcitabine and albumin-bound paclitaxel. Given the BRCA1 mutation, he had a higher likelihood of

Full access

It’s About Time!

Margaret Tempero

Compared with other malignancies, the treatment landscape for pancreatic cancer is pretty sparse. The last 2 drug approvals occurred several years ago and both drugs (albumin-bound paclitaxel and liposomal irinotecan) were formulated for better

Full access

Five Patients and One Important Lesson

Margaret Tempero

FOLFIRINOX or gemcitabine and nab-paclitaxel until 2010 or later. Talk about slow progress! Most of the patients I see will die of this disease. We can prolong their lives, but it is a temporary reprieve. Invariably, when I see a new patient, he or she

Full access

The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer

Mark T. Wakabayashi, Paul S. Lin, and Amy A. Hakim

Edited by Kerrin G. Robinson

debulking surgery . J Surg Oncol 1991 ; 48 : 39 – 44 . 4. McGuire WP Hoskins WJ Brady MF . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer . N Engl J Med 1996

Full access

Access to and Appropriateness of Cancer Care: Who Decides?

William T. McGivney

paclitaxel in combination be a treatment option for women with metastatic breast cancer. The vote of the NCCN Guidelines Panel on this issue was 15 to 0. The European Medicines Agency, the counterpart of the FDA for the European Union, has adopted a position

Full access

NCCN Guidelines Updates: Breast Cancer

Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar

single standard treatment exists for patients with small, node-negative, HER2-positive breast cancers, but there is evidence that chemotherapy might be useful in some. Tolaney et al 3 conducted a study of adjuvant paclitaxel (given weekly for 12 weeks

Full access

Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer

Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk

weekly paclitaxel, 2 single-arm phase II trials evaluated the utility of short-course docetaxel/cyclophosphamide (DCH for 4 cycles) 13 or paclitaxel (weekly for 12 weeks) 14 in combination with trastuzumab for low-risk HER2+ breast cancer. Both trials

Full access

Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer

Michael Karass, Rohan Bareja, Ethan Shelkey, Panagiotis J. Vlachostergios, Brian D. Robinson, Francesca Khani, Juan Miguel Mosquera, Douglas S. Scherr, Andrea Sboner, Scott T. Tagawa, Ana M. Molina, Olivier Elemento, David M. Nanus, and Bishoy M. Faltas

treated with trastuzumab, paclitaxel, carboplatin, and gemcitabine, 14 ERBB2 overexpression by IHC, gene amplification in the tumor by FISH, or presence in serum for extracellular ERBB2 domain testing by quantitative enzyme-linked immunosorbent assay was

Full access

Carcinosarcomas (Malignant Mixed Müllerian Tumor) of the Uterus: Advances in Elucidation of Biologic and Clinical Characteristics

Lauren E. Kernochan and Rochelle L. Garcia

Edited by Kerrin G. Robinson

chemotherapy regimens containing platinum . Gynecol Oncol 2008 ; 108 : 136 – 140 . 28 Homesley HD Filiaci V Markman M . Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group